Practical Diagnosis of Hematologic Disorders. Vol 2 Malignant Disorders
|
|
- Jerome Lane
- 5 years ago
- Views:
Transcription
1 5 th ed Practical Diagnosis of Hematologic Disorders Vol 2 Malignant Disorders Vol2_FrontMatter_v03_0804 final.indd i 8/6/ :00:11 PM
2 Authors Carl R Kjeldsberg, MD Professor of Pathology, University of Utah Health Sciences Center Chairman of the Board, ARUP Laboratories, Inc Sherrie L Perkins, MD, PhD Professor of Pathology, University of Utah Health Sciences Center Chief Medical Officer, Director of Laboratories, Medical Director of Hematopathology, ARUP Laboratories, In John Anastasi, MD Associate Professor, Associate Director Hematopathology Department of Pathology University of Chicago Medical Center Daniel A Arber, MD Professor and Associate Chair of Pathology for Clinical Services Stanford University David W Bahler, MD, PhD Associate Professor of Pathology, University of Utah Director, Hematologic Flow Cytometry Laboratory, ARUP Laboratories, Inc Robert C Blaylock, MD Professor of Pathology, Medical Director of University Hospital Transfusion Services and ARUP Blood Services Medical Director of the Immunohematology Reference Laboratory, ARUP Laboratories, Inc Co-Director of University Hospital Clinical Laboratories Kojo S J Elenitoba-Johnson, MD Professor of Pathology, Director of Division of Translational Research Director of Molecular Diagnostics Laboratory Director, Molecular Genetic Pathology Program University of Michigan Kathryn Foucar, MD Professor of Pathology, Vice Chair for Clinical Affairs University of New Mexico Health Sciences Center and TriCore Reference Laboratories Clinical Assistant Professor, Department of Pathology Stanford University Megan S Lim, MD, PhD Associate Professor of Pathology, Director of Hematopathology Director, Hematopathology Fellowship Training Program University of Michigan Robert W McKenna, MD Professor and Vice Chair for Academic Affairs Senior Consultant in Hematopathology, Department of Laboratory Medicine and Pathology Richard D Brunning Professor of Laboratory Medicine and Pathology University of Minnesota LoAnn C Peterson, MD Paul E Steiner Research Professor of Pathology, Feinberg Medical School Northwestern University, Northwestern Memorial Hospital George M Rodgers, MD, PhD Professor of Medicine and Pathology, University of Utah Health Sciences Center Medical Director, Coagulation Laboratory, ARUP Laboratories, Inc Mohamed E Salama, MD Assistant Professor of Pathology, University of Utah Health Sciences Center Assistant Medical Director, Hematopathology, ARUP Laboratories, Inc James W Vardiman, MD Professor of Pathology University of Chicago Medical Center Vol2_FrontMatter_v03_0804 final.indd ii 8/6/ :00:18 PM
3 Practical Diagnosis of Hematologic Disorders 5th Edition Vol 2 Malignant Disorders Carl R Kjeldsberg, MD Sherrie L Perkins, MD, PhD Editors et xiii alia ASCP Press American Society for Clinical Pathology Chicago, IL Vol2_FrontMatter_v03_0804 final.indd iii 8/6/ :00:19 PM
4 Publishing Team Erik Tanck (production/designer) Joshua Weikersheimer (publishing direction) Notice Trade names and equipment and supplies described herein are included as suggestions only. In no way does their inclusion constitute an endorsement or preferences by the American Society for Clinical Pathology. The ASCP did not test the equipment, supplies, or procedures and, therefore, urges all readers to read and follow all manufacturers instructions and package insert warnings concerning the proper and safe use of products. Copyright 2010 by the American Society for Clinical Pathology. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher. Printed in Singapore Vol2_FrontMatter_v03_0804 final.indd iv 8/6/ :00:19 PM
5 CONTENTS Vol 2 Malignant Disorders Preface xiii Acknowledgments xiv Part IX Myeloid Neoplasms MYELOPROLIFERATIVE NEOPLASMS 35. Chronic Myelogenous Leukemia, BCR-ABL John Anastasi, MD 36. Chronic Neutrophilic Leukemia 443 John Anastasi, MD 37. Polycythemia Vera 449 John Anastasi, MD 38. Primary Myelofibrosis 467 John Anastasi, MD 39. Essential Thrombocythemia 487 John Anastasi, MD 40. Chronic Eosinophilic Leukemia, NOS 501 Sherrie Perkins, MD, PhD Mohamed Salama, MD 41. Mastocytosis 509 Megan S Lim, MD, PhD 42. Myeloproliferative Neoplasms, Unclassifiable 521 John Anastasi, MD v Vol2_FrontMatter_v03_0804 final.indd v 8/6/ :00:19 PM
6 Practical Diagnosis of Hematologic Disorders MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA AND ABNORMALITIES OF PDGFRA, PDGFRB OR FGFR1 43. Myeloid and Lymphoid Neoplasms With Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1 Mohamed Salama, MD Sherrie Perkins, MD, PhD 44. Myelodysplastic/Myeloproliferative Neoplasms 535 Sherrie Perkins, MD, PhD MYELODYSPLASTIC SYNDROMES 45. Myelodysplastic Syndromes 547 Sherrie L Perkins, MD, PhD Robert W McKenna, MD Part X Acute Myeloid Leukemias ACUTE MYELOID LEUKEMIA AND RELATED PRECURSOR NEOPLASMS 46. Acute Myeloid Leukemia With Recurrent Genetic Abnormalities 585 Daniel A. Arber, MD 47. Acute Myeloid Leukemia With Myelodysplasia-Related Changes and Therapy-Related Myeloid Neoplasms 615 Daniel A Arber, MD 48. Acute Myeloid Leukemia, NOS 621 Daniel A Arber, MD 49. Myeloid Sarcoma 633 Daniel A Arber, MD 50. Myeloid Proliferations Related to Down Syndrome 639 Daniel A Arber, MD 51. Blastic Plasmacytoid Dendritic Cell Neoplasm 645 Daniel A Arber, MD vi Vol2_FrontMatter_v03_0804 final.indd vi 8/6/ :00:19 PM
7 Contents 52. Acute Leukemias of Ambiguous Lineage 653 Daniel A Arber, MD Part XI Lymphoid Neoplasms 53. Introduction to Non-Hodgkin Lymphoma 661 Kojo SJ Elenitoba-Johnson, MD Megan S Lim, MD, PhD Carl Kjeldsberg, MD Part XII Precursor Lymphoid Neoplasms 54. Precursor Lymphoid Neoplasms 691 Sherrie L Perkins MD, PhD Robert McKenna, MD Part XIII Mature B-Cell, T-Cell and Histiocytic Neoplasms MATURE B-CELL NEOPLASMS 55. Mature B-Cell Neoplasms With Leukemic Manifestations 723 LoAnn Peterson, MD 56. Mature B-Cell Neoplasms With Plasma Cell or Plasmacytoid Differentiation 747 LoAnn Peterson, MD 57. Mature B-Cell Neoplasms With Primary Tissue Manifestations 769 Kojo S J Elenitoba-Johnson, MD Megan S Lim, MD Carl Kjeldsberg, MD MATURE T-CELL AND NK-CELL NEOPLASMS 58. Mature T-Cell and NK-Cell Neoplasms 805 Kojo S J Elenitoba-Johnson, MD Megan S Lim, MD Carl Kjeldsberg, MD vii Vol2_FrontMatter_v03_0804 final.indd vii 8/6/ :00:20 PM
8 Practical Diagnosis of Hematologic Disorders HODGKIN LYMPHOMA 59. Hodgkin Lymphoma 835 Carl Kjeldsberg, MD Kojo S J Elenitoba-Johnson, MD HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS 60. Histiocytic and Dendritic Cell Neoplasms 853 Megan S Lim, MD, PhD POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS 61. Post-Transplant Lymphoproliferative Disorders 865 Megan S Lim, MD, PhD Part XIV Part XIV Special Techniques 62. Molecular Techniques in the Diagnosis of Hematologic Malignancies 879 Kojo S J Elenitoba-Johnson, MD 63. Flow Cytometric Analysis 899 David Bahler, MD, PhD Appendix Appendix: Hematology Reference Values 919 Index p index 2.1 and following viii Vol2_FrontMatter_v03_0804 final.indd viii 8/6/ :00:20 PM
9 Contents List of Tables Ch 35. Chronic Myelogenous Leukemia, BCR-ABL1+ t35.1 Features of Chronic Myelogenous Leukemia BCR-ABL1+, Chronic Phase 424 t35.2 WHO Critieria for Chronic Myelogeneous Leukemia, Accelerated Phase 428 t35.3 CML, Blast Phase 428 t35.4 Distinguishing Features Among the Chronic Myeloid Leukemias 436 t35.5 Summary of Features of Chronic Neutrophilic Leukemia (CNL) 437 Ch 37. Polycythemia Vera t37.1 Stages and Associated Features in Polycythemia Vera 449 t37.2 Classification of Polycythemia 452 t37.3 WHO Recommended Criteria for the Diagnosis of Polycythemia Vera 456 t37.4 Comparison of Findings in Polycythemia Vera and Secondary Erythrocytosis 457 Ch 38. Primary Myelofibrosis t38.1 Causes of Bone Marrow Fibrosis 468 t38.2 Major Clinical and Laboratory Features in PMF 470 t38.3 WHO Diagnostic Criteria for Primary Myelofibrosis 471 t38.4 Myeloid Disorders With Myelofibrosis 482 t38.5 Comparison of Usual Findings in Polycythemia Vera-Polycythemic Phase, PMF-Prefibrotic Stage, and Essential Thrombocythemia 482 Ch 39. Essential Thrombocythemia t39.1 Causes of Marked Thrombocytosis 487 t39.2 Features Helpful in Distinguishing Essential Thrombocythemia 489 and Secondary Thrombocytosis t39.3 Revised WHO (2008) Diagnostic Criteria for the Diagnosis 490 of Essential Thrombocythemia t39.4 Morphologic Features of ET 491 t39.5 Comparison of Features of Essential Thrombocythemia With Other Chronic Myeloproliferative Disorders 495 Ch 40. Chronic Eosinophilic Leukemia, NOS t40.1 Diagnostic Criteria of Chronic Eosinophilic Leukemia, NOS 502 t40.2 Systemic Involvement by Chronic Eosinophilic Leukemia, NOS 503 t40.3 Differential Diagnostic Consideration for Persistent Eosinophilia 506 Ch 41. Mastocytosis t41.1 Classification of Mast Cell Disease 510 (Adapted From World Health Organization Criteria) t41.2 Major and Minor Diagnostic Criteria for Systemic Mastocytosis 514 t41.3 Comparison of Immunophenotypes of Mast Cells and Closely Related Cell Types 519 Ch 42. Myeloproliferative Neoplasms, Unclassifiable t42.1 Situations in Which a Diagnosis of Myeloproliferative Neoplasm-Unclassifiable Can Be Considered 522 Ch 43. Myeloid and Lymphoid Neoplasms With Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1 t43.1 Fusion Partners of PDGFRB and Related Cytogenetic Defects 530 Occurring in Myeloid Neoplasms Presenting With Eosinophilia t43.2 FGFR1 Gene Fusion Partners 533 ix Vol2_FrontMatter_v03_0804 final.indd ix 8/6/ :00:21 PM
10 Practical Diagnosis of Hematologic Disorders Ch 44. Myelodysplastic/Myeloproliferative Neoplasms t44.1 Features Distinguishing Myelodysplastic Syndrome (MDS) 535 from Myeloproliferative Neoplasms (MPN) t44.2 WHO Classification of Myelodysplastic/Myeloproliferative Neoplasms 535 t44.3 Diagnostic Criteria for Chronic Myelomonocytic Leukemia 536 t44.4 Diagnostic Criteria for Atypical Chronic Myeloid Leukemia, BCR-ABL1 (acml) 540 t44.5 Comparison of Chronic Myelogenous Leukemia (CML) and Atypical Chronic Myelogenous Leukemia (acml) 541 t44.6 Diagnostic Criteria of Juvenile Myelomonocytic Leukemia 543 t44.7 Diagnostic Criteria for Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (MDS/MPN, U) 545 Ch 45. Myelodysplastic Syndromes t45.1 International Prognostic Scoring System (IPSS) Thresholds 548 for Cytopenias in the Diagnosis of Myelodysplastic Syndromes t45.2 WHO Classification of MDS 549 t45.3 Hematologic Findings in Myelodysplastic Syndromes 549 t45.4 Morphologic Abnormalities in Myelodysplastic Syndromes 551 t45.5 Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes 559 t45.6 International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes 561 t45.7 Chromosome Abnormalities Seen in MDS and Candidate Genes Affected 561 t45.8 Immunophenotypic Abnormalities Observed in Myelodysplastic Syndromes 562 t45.9 Peripheral Blood and Bone Marrow Findings in Myelodysplastic Syndromes 564 t45.10 Refractory Anemia (RA) 566 t45.11 Refractory Anemia With Ringed Sideroblasts (RARS) 569 t45.12 Refractory Cytopenia With Multilineage Dysplasia (RCMD) 570 t45.13 Refractory Anemia With Excess Blasts (RAEB) 572 t45.14 Myelodysplastic Syndrome With Isolated del(5q) 573 t45.15 Pediatric MDS 574 t45.16 WHO Minimal Diagnostic Criteria for Refractory Cytopenia of Childhood 575 t45.17 Comparison of Morphological Criteria of Hypoplastic Refractory Cytopenia 576 of Childhood and Aplastic Anemia t45.18 Differential Diagnostic Considerations in Myelodysplastic Syndromes 577 t45.19 Survival, Prognosis and Evolution to AML in Adult Patients with MDS 579 t45.20 Indicators of Good and Poor Prognosis in Myelodysplastic Syndromes 580 Ch 46. Acute Myeloid Leukemia (AML) With Recurrent Genetic Abnormalities t46.1 French-American-British (FAB) Classification Morphologic Categories of AML 586 t46.2 WHO 2008 Classification of Acute Myeloid Leukemia 586 t46.3 Cytologic Features of Blasts in Acute Myeloid and Acute Lymphoblastic Leukemias 587 t46.4 Cytochemical Stains and Their Utility 588 t46.5 Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group 590 for Clinical Cancer Research Composite Prognostic Index for Adult AML (age <60) t46.6 Common Variant Translocations of APL 600 t46.7 Common MLL Fusion Transcripts in AML 602 Ch 47. AML With Myelodysplasia-Related Changes and Therapy-Related Myeloid Neoplasms t47.1 Criteria for Diagnosis of AML With Myelodysplasia-Related Changes 616 Ch 48. AML, NOS t48.1 Differential Diagnosis of Acute Basophilic Leukemia (ABL) 630 Ch 49. Myeloid Sarcoma t49.1 Characteristics of Adult vs Pediatric Myeloid Sarcoma 635 x Vol2_FrontMatter_v03_0804 final.indd x 8/6/ :00:21 PM
11 Contents Ch 51. Blastic Plasmacytoid Dendritic Cell Neoplasm t51.1 Immunophenotypic Overlap Between Blastic Plasmacytoid Dendritic Cell Neoplasm 650 and Cases of Cutaneous Involvement by Acute Myeloid Leukemia t51.2 Distinguishing Blastic Plasmacytoid Dendritic Cell Neoplasm From CD56+ True NK-Cell, NK/T-Cell and γ/δ T-Cell Lymphoma/Leukemias 651 Ch 53. Introduction to Non-Hodgkin Lymphoma t53.1 Cytogenetic and Molecular Abnormalities in Non-Hodgkin Lymphoma 662 t53.2 Predisposing Conditions and Factors in the Development 663 of Non-Hodgkin Lymphoma t53.3 Comparison of Non-Hodgkin and Hodgkin Lymphomas 664 t53.4 Stages of Lymphoma 664 t53.5 National Cancer Institute Modified Staging for Intermediate- 664 and High-Grade Lymphomas t53.6 Staging Procedures for Non-Hodgkin Lymphoma 665 t53.7 Principles of Classification of Non-Hodgkin Lymphoma 666 t53.8 Mature Neoplasms 667 t53.9 Major Antibodies Used in Immunophenotyping of Malignant Lymphomas in Paraffin Sections t53.10 Application of Immunophenotypic Analysis 679 t53.11 Undifferentiated Large Neoplasm Antibody Panel for Paraffin Sections 679 t53.12 Immunophenotyping of Non-Hodgkin and Hodgkin Lymphomas 679 in Paraffin Sections t53.13 Comparison of Non-Hodgkin Lymphoma Features in Children and Adults 681 t53.14 Classification of Non-Hodgkin Lymphoma in Children 681 t53.15 Comparison of Morphologic and Immunophenotypic Features 682 in Childhood Non-Hodgkin Lymphomas t53.16 Causes of Lymph Node Enlargement Simulating Malignant Lymphoma 682 t53.17 International Prognostic Index of Parameters and Relative Risk 683 t53.18 International Prognostic Index: The International Index and Age-Adjusted Index 683 t53.19 Histopathology and Prognosis in Non-Hodgkin Lymphomas 684 t53.20 Cellular Prognostic in Non-Hodgkin Lymphomas 684 t53.21 Checklist for the Reporting of Lymphoid Neoplasms 685 t53.22 New Therapeutic Agents in Malignant Lymphoma 687 Ch 54. Precursor Lymphoid Neoplasms t54.1 WHO Classification of Acute Lymphoblastic Leukemia/Lymphoma 692 t54.2 Frequency of Clinical and Laboratory Findings at Diagnosis 693 in Children and Adults with ALL t54.3 Characteristic Clinical Features of Precursor T-ALL 693 t54.4 Distribution of White Cell Counts at Diagnosis 694 t54.5 FAB Morphologic Classification of Lymphoblasts 696 t54.6 Common Antigen Expression Patterns of Acute Lymphoblastic Leukemias/ Lymphoblastic Lymphomas 703 t54.7 Distribution of Immunophenotypic Subtypes in Acute Lymphoblastic Leukemia 703 t54.8 Correlation of Prognosis with Bone Marrow Cytogenetic Findings in ALL 707 t54.9 Cytogenetic Translocations Associated With Specific Molecular Genetic Abnormalities in ALL 711 t54.10 Most Significant Prognostic Indicators in Pediatric ALL 717 t54.11 Adverse Prognostic Factors in Adult and Pediatric ALL 717 Ch 55. Mature B-Cell Neoplasms With Leukemic Manifestations t55.1 Mature B-Cell Neoplasms With Leukemic Manifestations 723 t55.2 Rai Clinical Staging System for Chronic Lymphocytic Leukemia 724 t55.3 Binet Staging System for Chronic Lymphocytic Leukemia 724 t55.4 Typical Phenotypes of B-Cell Chronic Lymphoid Leukemias and Lymphomas 730 xi Vol2_FrontMatter_v03_0804 final.indd xi 8/6/ :00:22 PM
12 Practical Diagnosis of Hematologic Disorders Ch 56. Mature B-Cell Neoplasms With Plasma Cell or Plasmacytoid Differentiation t56.1 Mature B-Cell Neoplasms With Plasma Cell or Plasmacytoid Differentiation 747 t56.2 Monoclonal Immunoglobulins in Mature B-Cell Neoplasms 748 With Plasma Cell Differentiation t56.3 Approximate Incidence of Monoclonal Gammopathies in the United States 749 t56.4 Diagnostic Criteria for Monoclonal Gammopathy of Undetermined Significance 749 t56.5 Course of 241 Patients With Monoclonal Gammopathy 750 of Undetermined Significance t56.6 Diagnostic Criteria for Plasma Cell Myeloma 751 Ch 57. Mature B-Cell Neoplasms With Primary Tissue Manifestations t57.1 Mature B-Cell Neoplasms With Primary Tissue Manifestations 769 t57.2 Small Lymphocytic B-Cell Neoplasms: Characteristic Morphologic Features 770 t57.3 Small Lymphocytic B-Cell Neoplasms: Immunophenotypic Features 770 t57.4 Useful Features in the Differential Diagnosis of Mediastinal Lymphomas 794 Ch 58. Mature T-Cell and NK-Cell Neoplasms t58.1 Mature T-Cell and NK-Cell Neoplasms 805 t58.2 Differential Diagnosis of Neoplasms Expressing T-Cell and NK-Cell Markers 810 With Frequent Leukemic Presentation t58.3 Differential Diagnosis of Neoplasms Expressing T-Cell and NK-Cell Markers 825 With Frequent Cutaneous Involvement t58.4 Differential Diagnosis of Nodal Peripheral T-Cell Lymphoma, 827 Not Otherwise Specified t58.5 Characteristics of Variant ALK Translocations 832 Ch 59. Hodgkin Lymphoma t59.1 Staging Procedures in Hodgkin Lymphoma 837 t59.2 The Cotswald Modification of the Ann Arbor Staging Classification 837 for Hodgkin Lymphoma t59.3 World Health Organization (WHO) Classification of Hodgkin Lymphoma 837 t59.4 Immunophenotype Features of RS Cells and L&H Cells 839 t59.5 Differential Diagnosis of Hodgkin Lymphoma 839 t59.6 Immunophenotypic Distinction of Hodgkin Lymphoma From Non-Hodgkin Lymphoma 851 Ch 60. Histiocytic and Dendritic Cell Neoplasms t60.1 Immunophenotypic Features Useful in the Distinction of Macrophages, 854 Langerhans Cells, Dendritic Cells and Lymphocytes t60.2 Clinical Variants of Langerhans Cell Histiocytosis 856 t60.3 Differential Diagnosis of Langerhans Cell Histiocytosis 860 Ch 61. Post-Transplant Lymphoproliferative Disorders t61.1 Comparison of Post-Transplant Lymphoproliferative Disorders 866 Occurring in Solid Organ and Bone Marrow Transplant Patients t61.2 Evaluation for Diagnosis of PTLDs 867 t61.3 General Categories of Post-Transplantation Lymphoproliferative Disorders 868 Ch 62. Molecular Techniques in the Diagnosis of Hematologic Malignancies t62.1 Comparison of Molecular Methods Used in Diagnostic Hematopathology 880 t62.2 Genetic Alterations in Hematologic Malignancies Ch 63. Flow Cytometric Analysis t63.1 Fluorochromes Often Used With 488-nm Wavelength Excitation 900 t63.2 Common Hematopoietic Cell Antigens Evaluated With Flow Immunophenotyping 903 t63.3 Common Antigens Used to Assess Acute Leukemia Blast Lineage by Flow Cytometry 907 t63.4 Characteristic Phenotypic Features Associated with Specific Acute Leukemias 907 t63.5 Typical Immunophenotypes of Mature B-Cell Neoplasms 910 t63.6 Phenotypic Features Associated With Specific Mature T-Cell Neoplasms 913 xii Vol2_FrontMatter_v03_0804 final.indd xii 8/6/ :00:23 PM
13 Preface The goal of this book, beginning with the first edition in 1989, has been to provide an up-todate, concise source of guidelines to the selection, use and interpretation of laboratory tests, while at the same time providing an overview of the pathogenesis and clinical features of the most common hematologic disorders. Though the size and scope of this book have increased considerably, keeping pace with the expansion of the knowledge and diagnostic complexity in hematopathology, the focus on providing practical information has not changed. Each chapter follows a practical format to make finding specific information easy. This fifth edition contains substantial new information, particularly with regard to molecular modalities and utilization of ancillary testing in the diagnosis of hematologic disorders. The new edition uses the framework of the 2008 WHO classification for malignancies, and provides up-to-date diagnostic approaches, correct usage of laboratory testing, and algorithms for diagnosis of both benign and malignant disorders. We hope that this newest edition will be an even more valuable tool and resource for a broad audience, including pathologists, residents and fellows in pathology and medicine, hematologists/ oncologists, internists, pediatricians, medical students and medical technologists, as well as for those preparing for board examinations in pathology and internal medicine. We welcome your comments or suggestions for future editions and trust that this book will provide the quality information and education you ve come to expect. xiii Vol2_FrontMatter_v03_0804 final.indd xiii 8/6/ :00:23 PM
14 Acknowledgements We wish to express our appreciation to Joshua Weikersheimer of the ASCP Press, for his assistance in all aspects of publication, and to Susan Flinders for administrative assistance. We want to also thank our colleagues in the Department of Pathology at the University of Utah, and the staff at ARUP Laboratories for their support. Present and former hematopathology fellows have provided much inspiration Most of all, we are grateful for the support and love from our families, Gillean, Tanya, Kristina, Don, Rachel and Jessica. xiv Vol2_FrontMatter_v03_0804 final.indd xiv 8/6/ :00:23 PM
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More information2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Acute basophilic leukemia 9870/3 Acute biphenotypic leukemia [OBS] 9805/3 Acute erythroid leukemia 9840/3 Acute megakaryoblastic leukemia 9910/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid
More information2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Malignant lymphoma, NOS 9590/3 Non-Hodgkin lymphoma, NOS 9591/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma 9596/3 Primary
More informationIntegrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationCombinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation
Major subgroups according to the World Health Organisation (WHO) Classification Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationIntegrated Hematopathology. Morphology and FCI with IHC
Integrated Hematopathology Morphology and FCI with IHC FrontMatter.indd i 9/6/2009 9:30:12 PM FrontMatter.indd ii 9/6/2009 9:30:18 PM Integrated Hematopathology Morphology and FCI with IHC Cherie H Dunphy,
More informationChanges to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
More informationHEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor
HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor I. Description of the rotation: During this rotation, the resident will gain
More informationHematology Page 1 of 8
Hematology Page 1 of 8 Hematology Major Category Code Headings Revised 12/17 1 Basic methodology and test armamentarium 20000 2 Normal hematopoiesis & hemostasis 20100 3 RBC disorders, non-neoplastic 20340
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationWHO Classification 7/2/2009
Least Malignant Myeloproliferative Disorders Myelodysplastic Syndromes Most Malignant Acute Leukemia Classifying Hematopoietic Disorders French-American-British (FAB) World Health Organization (WHO) Thanks
More informationIntroduction: The Revised (4 th Edition) World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues
Society for Hematopathology Scientific Symposium USCAP Companion Meeting, Boston, MA March 8, 2009 Boston, MA Steven H. Swerdlow and James Vardiman, Moderators Introduction: The Revised (4 th Edition)
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationBone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More informationBone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More information2 nd step do Bone Marrow Study If possible both the aspiration and
Blood Malignancies-I Prof. Herman Hariman,SpPK a (KH). Ph.D.(U.K) Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. Clinpath, FK-USU First do the Full Blood Count Hb, WBCS, Platelets Morphology!! Such as blasts,
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationDiagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.
Diagnostic Approach for Eosinophilia and Mastocytosis Curtis A. Hanson, M.D. 2014 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2014 MFMER slide-2 Molecular Classification
More informationWHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that
More informationProtocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow*
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow* Version: Protocol Posting Date: January 2018 This protocol is NOT required for accreditation
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationWHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationThe primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:
Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist
More information12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
More informationThe College of American Pathologists offers these protocols
Strategies for Laboratory and Patient Management Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms of the Bone Marrow A Basis for Checklists LoAnn C. Peterson, MD; Steven
More informationWelcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
More informationTemplate for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Version: MPNBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is NOT required for accreditation
More informationCase #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...
Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More information2016 WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES, 4TH ED., VOL FCDS WEBCAST SERIES OCTOBER 19, 2017
2016 WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES, 4TH ED., VOL 2 2017-2018 FCDS WEBCAST SERIES OCTOBER 19, 2017 STEVEN PEACE, CTR 1 CDC & Florida DOH Attribution We acknowledge
More informationEosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation
Eosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation American Society for Clinical Pathology 2014 Annual Meeting Presented by: Matthew T. Howard, MD Assistant
More informationHypereosinophili c syndrome
Hypereosinophili c syndrome Eosinophilia Eosinophilia is commonly defined as an elevated percentage of eosinophils, with an absolute eosinophil count > 500 cells per cubic millimeter Secondary Primary
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationTemplate for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Template web posting date: December 2014 Authors Todd W. Kelley, MD, FCAP University of Utah and ARUP Laboratories,
More informationMyelodysplastic Syndromes: Everyday Challenges and Pitfalls
Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationNUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow
Quality ID #67 (NQF 0377): Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow National Quality Strategy Domain: Effective Clinical Care
More informationHematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow This measure may be used as an Accountability measure Clinical Performance
More informationContents. vii. Preface... Acknowledgments... v xiii
Contents Preface... Acknowledgments... v xiii SECTION I 1. Introduction... 3 Knowledge-Based Diagnosis... 4 Systematic Examination of the Lymph Node... 7 Cell Type Identification... 9 Cell Size and Cellularity...
More informationWhat is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification
What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification Rami Komrokji, MD Clinical Director Malignant Hematology Moffitt Cancer Center Normal Blood and Bone Marrow What is MDS Myelodysplastic
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationTHE SOCIETY FOR Hematopathology and the European
SPECIAL ARTICLE World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting Airlie House, Virginia, November
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationChanges to the 2016 WHO Classification for the Diagnosis of MDS
Changes to the 2016 WHO Classification for the Diagnosis of MDS Welcome to Managing MDS. I am Dr. Ulrich Germing, and today, I will provide highlights from the 14th International Symposium on MDS in Valencia,
More informationCorrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run
Corrigenda WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run In addition to corrections of minor typographical errors, corrections
More informationProtocol for the Examination of Hematologic Malignancies in Bone Marrow
Protocol for the Examination of Hematologic Malignancies in Bone Marrow Version: Bone Marrow 4.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of this protocol is recommended
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More informationMyelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression
Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Carlos E. Bueso-Ramos, M.D., Ph.D Department of Hematopathology The University of Texas M.
More informationBone Marrow IHC 0 Front Matter [Torlakovic].indd i 0 Front Matter [Torlakovic].indd i 8/18/ :30:45 AM 8/18/ :30:45 AM
Bone Marrow IHC 0 Front Matter [Torlakovic].indd i 8/18/2008 12:30:45 AM Dedication I dedicate this book to my husband Goran and to my children Lino, Jakov, Marija Milena, and Marta Danica Emina Emilia
More informationProtocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow Based on AJCC/UICC TNM, 7 th Edition Protocol web posting date: February 1, 2011 Procedures
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationHEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Hematology MOC exam blueprint Based on feedback from physicians that MOC assessments should
More informationMYELODYSPLASTIC AND MYELOPROLIFERATIVE
MYELODYSPLASTIC AND MYELOPROLIFERATIVE DISORDERS Pediatric Hemato-Oncology Division Medical Faculty University of Sumatera Utara 1 MYELODYSPLASIA SYNDROME A group of disorder defect in hematopoetic cell
More informationMYELOPROLIFERATIVE NEOPLASMS
9 : 2 MYELOPROLIFERATIVE NEOPLASMS Introduction William Dameshek in 1951 introduced the term Myeloproliferative disorders (MPD). This included polycythemia vera (PV), essential thrombocythemia (ET), primary
More informationNEWS FROM. Roswell Park s LEUKEMIA SERVICE
NEWS FROM Roswell Park s LEUKEMIA SERVICE MEET THE LEUKEMIA TEAM PATHOLOGY The Leukemia Service at Roswell Park Cancer Institute () is dedicated to quality patient care, innovative research, and the development
More information9/25/2017. Disclosure. I have nothing to disclose. Young S. Kim MD Dept. of Pathology
Disclosure MAST CELLNEOPLASM I have nothing to disclose. Young S. Kim MD Dept. of Pathology 1 Objectives What is mast cell lineage? Changes in updated WHO 2016 mastocytosis Issues of Mastocytosis CD30
More informationChronic Myeloproliferative Disorders
Chronic Myeloproliferative Disorders Chronic Myeloproliferative Disorders Cytogenetic and Molecular Genetic Abnormalities Editor Barbara J. Bain, London 15 figures, 4 in color, and 18 tables, 2003 ABC
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationUpdate on Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Kaaren Reichard Mayo Clinic Rochester
Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms Kaaren Reichard Mayo Clinic Rochester Reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Learning Objectives Present
More informationMyelodysplastic Syndrome Case 158
Myelodysplastic Syndrome Case 158 Dong Chen MD PhD Division of Hematopathology Mayo Clinic Clinical History 86 year old man Persistent borderline anemia and thrombocytopenia. His past medical history was
More information74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow
74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint
More informationReviewing the ICD-10 classification of haematological neoplasms on its way to ICD-11
WHO-FIC NETWORK MEETING Tokyo, Japan haematological neoplasms on its way to ICD-11 Ulrich Vogel, Robert Jakob, Michael Schopen, Harald Stein, Stefan Krause Abstract: haematological neoplasms on its way
More informationGroup of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and
Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood Classified based on cell type
More informationMolecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML
reprinted from november 2014 pathology laboratory medicine laboratory management Molecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML CAP TODAY and the Association for Molecular
More information2013 AAIM Pathology Workshop
2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone
More informationContents SECTION 1: PHYSIOLOGY OF BLOOD
Contents SECTION 1: PHYSIOLOGY OF BLOOD Chapter 1: Overview of Physiology of Blood 1 Normal Haematopoiesis 1 Red Blood Cells 6 White Blood Cells 15 Immune System 27 Megakaryopoiesis 32 Normal Haemostasis
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More information1. Challenging cases of eosinophilia (peripheral, bone marrow, or lymph node/tissue-based) falling into any of the following categories
Society for Hematopathology/European Association for Haematopathology 2019 Workshop Addressing the Challenges of Eosinophilia and Mastocytosis September 12-14, 2019, Phoenix, AZ https://www.sh-eahp.org/index.php/meetings
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationPathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
More informationReactive and Neoplastic Lymphocytosis
Reactive and Neoplastic Lymphocytosis Koranda A. Walsh, VMD, BS Assistant Professor, Clinical Pathobiology University of Pennsylvania School of Veterinary Medicine PLEASE NOTE: These notes are meant as
More informationContractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC A. LCD ID Number: L35032 Status: A-Approved
LCD for Flow Cytometry (L35032) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12501 Contractor Type: MAC A LCD ID Number: L35032 Status: A-Approved Contractor Information LCD Information
More informationCLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98
PAGE: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationApproaching myeloid neoplasms: diagnostic algorithms
Approaching myeloid neoplasms: diagnostic algorithms Alexandar Tzankov Histopathology Pathology Content Integration of clinical and laboratory data Bone marrow evaluation approaching Myeloproliferative
More informationJuly 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
July 3, 2013 The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Physician Compare Intelligent Search To Whom it May Concern, The American
More informationProtocol. Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Myelodysplastic Syndromes and Myeloproliferative Neoplasms (80121) (Formerly Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms) Medical Benefit Effective
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More informationNEWS FROM. Roswell Park s LEUKEMIA SERVICE
NEWS FROM Roswell Park s LEUKEMIA SERVICE MEET THE LEUKEMIA TEAM The Leukemia Service at Roswell Park Cancer Institute (RPCI) is dedicated to quality patient care, innovative research, and the development
More informationCharacterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases
Article Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases Keming Lin 1,*, Gang Xu 1, Jie-Gen Jiang 1, Mayuko Imai 1, Zhao Wu 1, Paris Petersen 1, Kim Janatpour 1, and Bashar
More informationBlood Cell Identification: 2011-B Mailing: Acute Myeloid Leukemia (AML)
Please Note: To view the Figures and Images contained within this education activity in color, access the electronic version of the reading. CASE HISTORY This peripheral blood smear is from a 51-year-old
More informationSaudi Fellowship Training Program. Final Written Examination of Adult Hematology 2018
Saudi Fellowship Training Program Final Written Examination of Adult Hematology 2018 Objectives: Determine the quantity and quality of a hematologist s knowledge base ranked as competent, so that the individual
More informationHematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationMyeloproliferative Neoplasms
Myeloproliferative Neoplasms (MPN and MDS/MPN) Attilio Orazi, MD, FRCPath Weill Cornell Medical College/ NY Presbyterian Hospital, New York, NY USA EAHP EDUCATIONAL SESSION: Updated WHO classification
More information